S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
S&P 500   4,219.73 (+0.95%)
DOW   33,115.80 (+0.63%)
QQQ   351.32 (+0.96%)
AAPL   179.91 (+1.50%)
MSFT   330.80 (+0.73%)
META   270.83 (+2.31%)
GOOGL   123.35 (+0.39%)
AMZN   122.69 (+1.75%)
TSLA   205.00 (+0.52%)
NVDA   394.40 (+4.24%)
NIO   7.49 (-0.53%)
BABA   82.91 (+4.22%)
AMD   119.75 (+1.30%)
T   15.81 (+0.51%)
F   12.05 (+0.42%)
MU   69.15 (+1.39%)
CGC   0.84 (+0.60%)
GE   104.50 (+2.93%)
DIS   88.67 (+0.81%)
AMC   4.60 (+2.22%)
PFE   38.01 (-0.03%)
PYPL   63.17 (+1.90%)
NFLX   403.15 (+2.00%)
NASDAQ:BEAM

Beam Therapeutics (BEAM) Stock Forecast, Price & News

$32.36
+0.46 (+1.44%)
(As of 12:22 PM ET)
Compare
Today's Range
$31.26
▼
$32.61
50-Day Range
$29.32
▼
$35.99
52-Week Range
$28.04
▼
$73.27
Volume
156,658 shs
Average Volume
897,642 shs
Market Capitalization
$2.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$67.91
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Beam Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
113.6% Upside
$67.91 Price Target
Short Interest
Bearish
21.04% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.48mentions of Beam Therapeutics in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$288,945 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.50) to ($6.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

1645th out of 1,980 stocks

Biological Products, Except Diagnostic Industry

271st out of 330 stocks

See Top Rated MarketRank™ Stocks Here

BEAM stock logo

About Beam Therapeutics (NASDAQ:BEAM) Stock

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

Receive BEAM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Beam Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

BEAM Stock News Headlines

May 30, 2023 | finance.yahoo.com
Global Radiation Therapy Market Report 2023: Featuring Ion Beam Applications, Siemens Healthineers, Accuray, Elekta, ViewRay & Hitachi
May 30, 2023 | finance.yahoo.com
Global Radiation Therapy Market Report 2023: Surface-Guided Radiotherapy Boosts Sector
June 1, 2023 | Edge On The Street (Ad)
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
May 30, 2023 | finance.yahoo.com
GT Medical Technologies Marks a Clinical Milestone: 200th Patient Enrolled in the Multicenter Observational Registry of GammaTile® Therapy
May 29, 2023 | msn.com
Pioneering proton beam therapy treated my breast cancer
May 27, 2023 | msn.com
Yakuza Kiwami 2: Unlock Beam’s Secret Weapon Shop (Beam's Backroom Cache Substory)
May 25, 2023 | markets.businessinsider.com
Genome Medical Supporting Beam Therapeutics on its Sickle Cell Disease Clinical Trial
May 20, 2023 | seekingalpha.com
Beam Therapeutics: Base Editing Leader With Major Catalyst Next Year
June 1, 2023 | Edge On The Street (Ad)
Graphite Shortage Could Derail the $7 Trillion EV Transition
Graphite (not lithium) is expected to see the largest increase in demand of all battery metals over the next decade. But projections warn of an 8 million ton shortfall of graphite by 2040. That's why 97 more graphite mines are needed just to keep up with battery production for the $7 trillion transition to electric vehicles.
May 18, 2023 | msn.com
Proton therapy, touted as cancer killer without side effects, set for Israel debut
May 17, 2023 | americanbankingnews.com
Beam Therapeutics Inc. (NASDAQ:BEAM) Forecasted to Earn Q2 2023 Earnings of ($1.18) Per Share
May 16, 2023 | yahoo.com
The Distillery Behind Jim Beam Is Releasing Its First American Single Malt Whiskey
May 16, 2023 | msn.com
Tata Memorial now 1st govt facility in India to offer breakthrough ‘proton therapy’ for cancer
May 16, 2023 | finance.yahoo.com
Cathie Wood Is Loading Up on These 3 Stocks Down 70% or More. Should You?
May 16, 2023 | americanbankingnews.com
Brokers Issue Forecasts for Beam Therapeutics Inc.'s Q2 2023 Earnings (NASDAQ:BEAM)
May 16, 2023 | americanbankingnews.com
Beam Therapeutics Inc. (NASDAQ:BEAM) Forecasted to Post Q2 2023 Earnings of ($1.15) Per Share
May 15, 2023 | marketwatch.com
Proton Beam Therapy Equipment Market New Insight Report | 2023-2031
May 14, 2023 | americanbankingnews.com
Barclays Trims Beam Therapeutics (NASDAQ:BEAM) Target Price to $41.00
May 12, 2023 | msn.com
Barclays Maintains Beam Therapeutics (BEAM) Equal-Weight Recommendation
May 12, 2023 | msn.com
Citigroup Maintains Beam Therapeutics (BEAM) Buy Recommendation
May 12, 2023 | msn.com
Citigroup Maintains Beam Therapeutics (BEAM) Buy Recommendation
May 12, 2023 | americanbankingnews.com
Beam Therapeutics (NASDAQ:BEAM) PT Lowered to $42.00
May 11, 2023 | marketwatch.com
8-K: Beam Therapeutics Inc.
May 11, 2023 | msn.com
Proton therapy comes to public sector now
May 11, 2023 | msn.com
External beam radiation for prostate cancer
May 11, 2023 | marketwatch.com
Proton Beam Therapy Equipment Market Research, 2030
May 11, 2023 | markets.businessinsider.com
Beam Therapeutics (BEAM) Gets a Hold from Barclays
See More Headlines

BEAM Price History

BEAM Company Calendar

Last Earnings
5/10/2023
Today
6/01/2023
Next Earnings (Estimated)
8/08/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BEAM
CUSIP
N/A
CIK
1745999
Web
www.beamtx.com
Phone
857-327-8775
Fax
N/A
Employees
341
Year Founded
2017

Price Target and Rating

Average Stock Price Forecast
$67.91
High Stock Price Forecast
$105.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+111.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($4.45)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-289,090,000.00
Net Margins
-412.45%
Pretax Margin
-374.76%
Return on Equity
-42.04%
Return on Assets
-23.25%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.92
Quick Ratio
4.92

Sales & Book Value

Annual Sales
$60.92 million
Price / Sales
40.27
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.99 per share
Price / Book
3.22

Miscellaneous

Outstanding Shares
76,220,000
Free Float
72,863,000
Market Cap
$2.45 billion
Optionable
Not Optionable
Beta
1.63

Social Links


Key Executives

  • Mr. John M. Evans M.B.A.Mr. John M. Evans M.B.A. (Age 45)
    CEO & Director
    Comp: $1.02M
  • Dr. Giuseppe Ciaramella Ph.D. (Age 54)
    Pres & Chief Scientific Officer
    Comp: $890.79k
  • Ms. Terry-Ann Burrell M.B.A.Ms. Terry-Ann Burrell M.B.A. (Age 46)
    CFO & Treasurer
    Comp: $687.52k
  • Dr. Feng Zhang Ph.D.
    Co-Founder
  • Dr. David R. Liu Ph.D.
    Co-Founder
  • Dr. J. Keith Joung M.D.
    Ph.D., Co-Founder
  • Dr. Nicole Gaudelli Ph.D.
    Co-Founder
  • Dr. Alexis Komor Ph.D.
    Co-Founder
  • Ms. Suzanne Fleming (Age 62)
    Chief Accounting Officer
  • Mr. Brian Riley (Age 46)
    Sr. VP of Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BEAM Stock - Frequently Asked Questions

Should I buy or sell Beam Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Beam Therapeutics in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" BEAM shares.
View BEAM analyst ratings or view top-rated stocks.

What is Beam Therapeutics' stock price forecast for 2023?

10 analysts have issued 12 month price targets for Beam Therapeutics' stock. Their BEAM share price forecasts range from $37.00 to $105.00. On average, they expect the company's stock price to reach $67.91 in the next year. This suggests a possible upside of 111.0% from the stock's current price.
View analysts price targets for BEAM or view top-rated stocks among Wall Street analysts.

How have BEAM shares performed in 2023?

Beam Therapeutics' stock was trading at $39.11 on January 1st, 2023. Since then, BEAM shares have decreased by 17.7% and is now trading at $32.19.
View the best growth stocks for 2023 here.

When is Beam Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023.
View our BEAM earnings forecast.

How were Beam Therapeutics' earnings last quarter?

Beam Therapeutics Inc. (NASDAQ:BEAM) announced its quarterly earnings data on Wednesday, May, 10th. The company reported ($1.33) EPS for the quarter, topping the consensus estimate of ($1.36) by $0.03. The firm earned $24.21 million during the quarter, compared to the consensus estimate of $14.41 million. Beam Therapeutics had a negative net margin of 412.45% and a negative trailing twelve-month return on equity of 42.04%.

What ETFs hold Beam Therapeutics' stock?

ETFs with the largest weight of Beam Therapeutics (NASDAQ:BEAM) stock in their portfolio include Kelly CRISPR & Gene Editing Technology ETF (XDNA), ARK Genomic Revolution ETF (ARKG), iShares Genomics Immunology and Healthcare ETF (IDNA), ARK Innovation ETF (ARKK), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), Jacob Forward ETF (JFWD) and SPDR S&P Biotech ETF (XBI).

What other stocks do shareholders of Beam Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Beam Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Editas Medicine (EDIT), Cisco Systems (CSCO), Block (SQ), Skyworks Solutions (SWKS), Akoustis Technologies (AKTS), Invitae (NVTA), QUALCOMM (QCOM) and Alector (ALEC).

When did Beam Therapeutics IPO?

(BEAM) raised $101 million in an IPO on Thursday, February 6th 2020. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Barclays served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What is Beam Therapeutics' stock symbol?

Beam Therapeutics trades on the NASDAQ under the ticker symbol "BEAM."

Who are Beam Therapeutics' major shareholders?

Beam Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (11.84%), FMR LLC (8.15%), BlackRock Inc. (7.08%), Temasek Holdings Private Ltd (5.48%), Farallon Capital Management LLC (4.60%) and State Street Corp (4.25%). Insiders that own company stock include Fmr Llc, Giuseppe Ciaramella, Graham K Cooper, John M Evans, John M Evans and Terry-Ann Burrell.
View institutional ownership trends.

How do I buy shares of Beam Therapeutics?

Shares of BEAM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Beam Therapeutics' stock price today?

One share of BEAM stock can currently be purchased for approximately $32.19.

How much money does Beam Therapeutics make?

Beam Therapeutics (NASDAQ:BEAM) has a market capitalization of $2.45 billion and generates $60.92 million in revenue each year. The company earns $-289,090,000.00 in net income (profit) each year or ($4.45) on an earnings per share basis.

How many employees does Beam Therapeutics have?

The company employs 341 workers across the globe.

Does Beam Therapeutics have any subsidiaries?
The following companies are subsidiares of Beam Therapeutics: Blink Therapeutics Inc..
Read More
How can I contact Beam Therapeutics?

Beam Therapeutics' mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The official website for the company is www.beamtx.com. The company can be reached via phone at 857-327-8775 or via email at investors@beamtx.com.

This page (NASDAQ:BEAM) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -